Health Care · Services-Offices & Clinics of Doctors of Medicine

TOI Oncology Institute, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1799191105 filings
Russell 2000

TOI at a glance

Oncology Institute, Inc. (TOI, SEC CIK 1799191) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Oncology Institute, Inc. (TOI) reported revenue of $502.7 million (up 27.8% from FY2024) and a net loss of $60.6 million. Diluted EPS was -$0.54.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Oncology Institute, Inc. (TOI) shares worth $125.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Chernett Jorey on November 11, 2026 of 1,391 shares at $0.80 per share.
  • In the last 90 days, TOI insiders reported 1 open-market purchase ($176K) and 1 open-market sale ($11.4M) on Form 4, a net sale of $11.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$502.7M
+27.8% vs prior year
Insiders · 90 days
1 buy · 1 sell
Net −$11.2M
13F holders
24 funds
$125.3M · −1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
  • Carried-forward risks include assumptions, uncertainties, and other factors that could adversely affect business performance
  • Future SEC filings may disclose changes to existing risks or additional risk factors

Management Discussion & Analysis

  • Revenue $169.8M, up 24.3% YoY from $136.6M
  • Net loss margin 9.2% vs 12.2% YoY, operating loss margin 1.7% vs 6.0%
  • Best segment, Specialty Pharmacy revenue $109.3M, up 44.0%; patient services $60.0M, down 0.3%
  • Cash $36.9M, operating cash flow $19.9M, senior secured term-loan proceeds $75.0M
  • Near-term liquidity sufficient for at least one year, with $134.5M in material cash requirements disclosed

AI summary of the TOI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor presentation furnished as Exhibit 99.1 for use in investor meetings
  • Presentation may contain material updates on Starling Oncology’s strategy, pipeline, or outlook requiring review before investment decisions

Item EX-99.1: Item EX-99.1

  • Investor presentation outlines oncology value-based care model across capitation, fee-for-service, specialty pharmacy, and clinical services
  • FY2026 revenue guidance $650–660M, adjusted EBITDA $4–6M, and free cash flow $5–10M
Filed Nov 12, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated investor presentation supersedes the prior Exhibit 99.1 presentation
  • Revised materials intended for investor meetings, potentially updating Starling Oncology’s strategic and financial messaging

Item EX-99.1: Item EX-99.1

  • Investor presentation highlights Starling’s oncology value-based-care platform, combining capitated care, fee-for-service, specialty pharmacy, and clinical services
  • FY2026 revenue guidance $650M-$660M, with Adjusted EBITDA guidance $4M-$6M and free cash flow guidance $5M-$10M
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Starling Oncology’s financial results for the three months ended September 30, 2026
  • Exhibit 99.1 contains the company’s financial figures and additional financial information

Item EX-99.1: Item EX-99.1

  • Q3 revenue $169.8M, up 24.3%, led by Specialty Pharmacy revenue $109.3M, up 44%
  • Adjusted EBITDA $3.4M versus $(3.5)M, marking a second consecutive positive quarter despite $15.7M net loss

AI summaries of TOI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TOI

Don't miss the next TOI filing

  • Alerts as it files. A push when TOI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TOI, by share count.
  • Ask anything. An AI agent that reads every TOI filing and answers with sources.

TOI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Virnich DanielJNov 17, 2026$3.40
Podnos YaleJNov 17, 2026$3.40
Carter Robert RossJNov 17, 2026$3.40
Podnos YaleJNov 12, 2026$3.76
Chernett JoreyBuyNov 11, 2026$0.80
Chernett JoreyBuyNov 11, 2026$0.80
Chernett JoreyBuyNov 10, 2026$0.67
Chernett JoreyBuyNov 9, 2026$0.54

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$393.4M$502.7M
Operating Income--$60.1M-$36.1M
Net Income-$83.1M-$64.7M-$60.6M
Op. Margin--15.3%-7.2%
Net Margin--16.4%-12.1%
Balance Sheet
Total Assets$209.2M$172.7M$164.7M
Equity-$3.6M-$15.7M
ROE--1801.7%385.5%
Per Share
EPS$-0.92$-0.71$-0.54
Cash Flow
Operating CF--$26.5M-$24.6M
CapEx$4.6M$3.8M$3.2M

Source: XBRL data in Oncology Institute, Inc. (TOI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TOI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TOI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$125.3M
Q2 202625$96.4M
Q1 202623$46.3M
Q4 202522$49.1M
Q3 202522$44.9M
Q2 202519$21.9M
Q1 202510$2.9M
Q4 20245$688,000
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TOI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 17, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
8-KNov 12, 2026Analysis-
8-KNov 12, 2026Analysis-
4Nov 10, 2026--
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
8-KSep 2, 2026Analysis-
4Aug 24, 2026--
8-KAug 21, 2026Analysis-
4Aug 17, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KAug 3, 2026Analysis-
4Jul 29, 2026--
4Jul 29, 2026--
4Jul 29, 2026--
4Jul 29, 2026--
4Jul 29, 2026--
4Jul 29, 2026--
4Jul 29, 2026--

Related Health Care companies

All Health Care →

TOI SEC filings: frequently asked questions

Are TOI insiders buying or selling?

In the last 90 days, Oncology Institute, Inc. (TOI) officers, directors and 10% owners reported 1 open-market purchase worth $176,273 by 1 insider and 1 open-market sale worth $11.4 million by 1 insider on Form 4, a net sale of $11.2 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TOI stock?

As of September 30, 2026, the largest Oncology Institute, Inc. (TOI) holders among the 13F filers tracked by SignalX were BlackRock ($33.7 million), Vanguard Capital Management LLC ($21.9 million), State Street Corp ($12.5 million), Goldman Sachs Group ($7.6 million), Renaissance Technologies LLC ($7.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TOI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Oncology Institute, Inc. (TOI) reported revenue of $502.7 million (up 27.8% from FY2024) and a net loss of $60.6 million. Diluted EPS was -$0.54. The figures come from the XBRL data in the 10-K.

What did TOI report in its latest 8-K?

Oncology Institute, Inc. (TOI) filed an 8-K on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor presentation furnished as Exhibit 99.1 for use in investor meetings.

What are the latest TOI SEC filings?

Oncology Institute, Inc. (TOI) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 19, 2026.

What is TOI's SEC CIK number?

Oncology Institute, Inc. (TOI)'s SEC Central Index Key (CIK) is 1799191. EDGAR lists every TOI filing under that number.

Ask anything about TOI

The research agent reads TOI's filings, financials, insider trades and 13F holders, then answers with sources.